For the quarter ended September 2025, Axsome Therapeutics (AXSM Quick QuoteAXSM - Free Report) reported revenue of $170.99 million, up 63.2% over the same period last year. EPS came in at -$0.94, compared to -$1.34 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $164.05 million, representing a surprise of +4.23%. The company delivered an EPS surprise of -14.63%, with the consensus EPS estimate being -$0.82.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Axsome performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Royalty: $1.21 million compared to the $1.36 million average estimate based on nine analysts. The reported number represents a change of +17.7% year over year.
• Revenues- Product sales, net: $169.78 million compared to the $161.33 million average estimate based on nine analysts. The reported number represents a change of +63.7% year over year.
• Product Sales, net- Sunosi: $32.8 million versus $29.34 million estimated by six analysts on average.
• Product Sales, net- Auvelity: $136.1 million versus the six-analyst average estimate of $129.77 million.

View all Key Company Metrics for Axsome here>>>

Shares of Axsome have returned +12.2% over the past month versus the Zacks S&P 500 composite's +2.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.